About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
ISSN 0300-9092 (Print)
ISSN 2412-5679 (Online)
About
The Journal "Obstetrics and Gynecology"Journal HistoryAims and ScopePolicies on Conflict of Interest, Human and Animal Rights, and Informed ConsentEditorial ProcessData sharing statementAdvertising PolicyThe Process for Handling Cases Requiring Corrections, Retractions, and Editorial Expressions of ConcernEditorial BoardEditorial CounsilInformation for ProfessionalsNewsContacts
ArchiveEthical StandardsSubscription
For authors
InstructionsInformed consent policyContract offerEASE GuidelinesICJME CriteriaWAME Recommendations on ChatGPT and Chatbots in Relation to Scholarly Publications
Reviewing
Procedure for reviewingReviewers 2023-2024
Logout
Obstetrics and Gynegology2026№8

Incretin receptor agonists and PMOS: pathogenetic rationale for therapy

DOI
https://dx.doi.org/10.18565/aig.2026.282

Yarmolinskaya M.I., Yureneva S.V., Cherkashina S.A.

1) D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductive Medicine, St. Petersburg, Russia; 2) I.I. Mechnikov North-Western State Medical University, Ministry of Health of Russia, St. Petersburg, Russia; 3) Academician V.I. Kulakov National Medical Research Centre for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia, Moscow, Russia

Polyendocrine metabolic ovarian syndrome (PMOS), which emphasizes the systemic nature and terminologically expands the etiopathogenesis of polycystic ovary syndrome (PCOS), is an important medical and social problem. Its significance stems from its impact on women’s well being and its negative demographic effects. Forecasts show no considerable rise in the global birth rate in the coming years. Since PMOS is linked to anovulatory infertility and miscarriage risk, it is crucial to enhance diagnostic approaches, deepen understanding of its pathogenesis, and refine treatment strategies. Overweight, obesity, insulin resistance, and related metabolic and cardiovascular disorders in women with PMOS substantially threaten their health and quality of life.
Current data on the etiopathogenesis of PMOS are systematized, with a focus on the multifactorial nature of the disease. Incretins have been studied: their role in PMOS pathogenesis and their metabolic and reproductive effects are described. The potential applications of incretin receptor agonists (GLP-1RAs, GLP-1RA/GIPRAs) in the treatment of PMOS are analyzed. Their effects on weight loss, correction of insulin resistance, lipid and carbohydrate metabolism, and impact on reproductive function are demonstrated. The limitations and specific features of incretin therapy are outlined, including issues related to contraception and pregnancy planning.
Conclusion. Despite the variety of available pharmacological approaches, the basic recommendation for correcting PMOS remains lifestyle modification. Bioinformatic methods help identify new therapeutic targets by analyzing disease mechanisms and promising intervention points. Large-scale research is required to develop reliable and scientifically supported recommendations.

Authors’ contributions. Yarmolinskaya M.I., Yureneva S.V. – developing the concept and design of the study; Yarmolinskaya M.I., Yureneva S.V., Cherkashina S.A. – data collection, data analysis and conclusions, preparation of the manuscript.
Conflicts of interest. Authors declare lack of the possible conflicts of interests.
Funding. The article was published with the financial support from Geropharm Ltd. 
Generative Artificial Intelligence. In preparing the article, Gemini 3 PRO AI was used to rephrase and improve readability. The resulting content was reviewed, edited, and approved by the authors. The authors are fully responsible for the accuracy of the publication’s content.
For citation: Yarmolinskaya M.I., Yureneva S.V., Cherkashina S.A. Incretin receptor agonists and 
polyendocrine metabolic ovarian syndrome: pathogenetic rationale for therapy.
Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2026; (8): 43-54 (in Russian)
https://dx.doi.org/10.18565/aig.2026.282

Keywords

polycystic ovary syndrome
PCOS
polyendocrine metabolic ovarian syndrome
PMOS
GLP-1RA/GIPRAs
tirzepatide
Full text (in Russian)

References

  1. Eiras M.C., Pinheiro D.P., Romcy K.A.M., Ferriani R.A., Reis R.M.D., Furtado C.L.M. Polycystic ovary syndrome: the epigenetics behind the disease. Reprod. Sci. 2022; 29(3): 680-94. https://dx.doi.org/10.1007/43032-021-00516-3
  2. Chen Y., Sun X., Xia X., Chen K., Zeng F. The pathogenesis, therapeutic targets and drugs of polycystic ovary syndrome. Front. Endocrinol. (Lausanne). 2025; 16: 1722649. https://dx.doi.org/10.3389/fendo.2025.1722649
  3. Bahri Khomami M., Shorakae S., Hashemi S., Harrison C.L., Piltonen T.T., Romualdi D. et al. Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Nat. Commun. 2024; 15(1): 5591. https://dx.doi.org/10.1038/s41467-024-49749-1
  4. Zheng L., Xu X., Zhou J.Z., Hong L., He Y.F., Fang Y.X. et al. The burden of polycystic ovary syndrome-related infertility in 204 countries and territories, 1990-2021: an analysis of the global burden of disease study 2021. Front. Endocrinol. (Lausanne). 2025; 16: 1559246. https://dx.doi.org/10.3389/fendo.2025.1559246
  5. United Nations. World Fertility 2024. UN DESA/POP/2024/TR/NO.11. New York: United Nations. Available at: https://www.un.org/development/desa/pd/sites/www.un.org.development.desa.pd/files/undesa_pd_2025_wfr_2024_final.pdf
  6. Федоров Д.Ю. Демографический вызов России. Итоги 2025 г. (Аналитический обзор). Перспективы. Электронный журнал. 2025; 4(43): 126-31. https://dx.doi.org/10.32726/2411-3417-2025-4-126-131 [Fedorov D.Y. Russia’s Demographic Challenge: Results of 2025 (Analytical Review). Perspektivy. Electronic Journal. 2025; 4(43): 126-31 (in Russian). https://dx.doi.org/10.32726/2411-3417-2025-4-126-131].
  7. Teede H.J., Tay C.T., Laven J.J.E., Dokras A., Moran L.J., Piltonen T.T. et al. Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J. Clin. Endocrinol. Metab. 2023; 108(10): 2447-69. https://dx.doi.org/10.1210/clinem/dgad463
  8. Song E., Fang Y., Li X., Fu W., He H., Gao Z. et al. Balancing metabolic optimization and reproductive safety in polycystic ovary syndrome: a Bayesian-informed framework for GLP-1 receptor agonists. Front. Nutr. 2026; 13: 1809416. https://dx.doi.org/10.3389/fnut.2026.1809416
  9. Zhang J., Zhu Y., Wang J., Hu H., Jin Y., Mao X. et al. Global burden and epidemiological prediction of polycystic ovary syndrome from 1990 to 2019: A systematic analysis from the Global Burden of Disease Study 2019. PLoS One. 2024; 19(7): e0306991. https://dx.doi.org/10.1371/journal.pone.0306991
  10. Pena A.S., Witchel S.F., Boivin J., Burgert T.S., Ee C., Hoeger K.M. et al. International evidence-based recommendations for polycystic ovary syndrome in adolescents. BMC Med. 2025; 23(1): 151. https://dx.doi.org/10.1186/s12916-025-03901-w
  11. Bousamri A., Al-Shehri M., Kana'an M., Almutairi T., Alharbi F., Aburezq A. et al. Retinal and choroidal structural and microvascular characteristics in women with polycystic ovary syndrome: A systematic review and meta-analysis of Optical Coherence Tomography (OCT) and OCT Angiography (OCTA) studies. Cureus. 2026; 18(3): e104504. https://dx.doi.org/10.7759/cureus.104504
  12. Teede H.J., Khomami M.B., Morman R., Laven J.S.E., Joham A.E., Costello M.F. et al. Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: a multistep global consensus process. Lancet. 2026; 407(10545): 2329-39. https://dx.doi.org/10.1016/S0140-6736(26)00717-8
  13. Sharma P., Jain M., Tripathi M., Sharma M., Halder A. An update on the genetics of polycystic ovary syndrome. J. Endocrinol. Reprod. 2023: 27(4): 217-40. https://dx.doi.org/10.18311/jer/2023/34654
  14. Cepero-Gonzalez M.d.l.A., Aguilar-Galarza A., Rodriguez-Garcia V.M., Garcia-Gasca T., Moreno Celis U. Diagnostic criteria and genetic basis of polycystic ovary syndrome: a narrative review. Metabolites. 2026;16(4): 277. https://dx.doi.org/10.3390/metabo16040277
  15. Белова И.С., Хащенко Е.П., Уварова Е.В. Современные аспекты роли инсулинорезистентности, системного воспаления и оксидативного стресса в патогенезе гиперандрогении и нарушений фолликулогенеза у пациенток с синдромом поликистозных яичников. Акушерство и гинекология. 2021; 5: 55-63. https://dx.doi.org/10.18565/aig.2021.5.55-63 [Belova I.S., Khashchenko E.P., Uvarova E.V. Current aspects of the role of insulin resistance, systemic inflammation, and oxidative stress in the pathogenesis of hyperandrogenism and abnormal folliculogenesis in patients with polycystic ovary syndrome. Obstetrics and Gynecology. 2021; (5): 55-63 (in Russian). https://dx.doi.org/10.18565/aig.2021.5.55-63].
  16. Szeliga A., Rudnicka E., Maciejewska-Jeske M., Kucharski M., Kostrzak A., Hajbos M. et al. Neuroendocrine determinants of polycystic ovary syndrome. Int. J. Environ. Res. Public Health. 2022; 19(5): 3089. https://dx.doi.org/10.3390/ijerph19053089
  17. Moore A.M., Coolen L.M., Porter D.T., Goodman R.L., Lehman M.N. KNDy cells revisited. Endocrinology. 2018; 159(9): 3219-34. https://dx.doi.org/10.1210/en.2018-00389
  18. Ярмолинская М.И., Ганбарли Н.Ф., Ткаченко Н.Н., Николаева В.И., Толибова Г.Х., Траль Т.Г., Рулев В.В., Цыпурдеева А.А. Кисспептин и синдром поликистозных яичников - есть ли связь? Журнал акушерства и женских болезней. 2017; 66(6): 73-80. https://dx.doi.org/10.17816/JOWD66673-80 [Yarmolinskaya M.I., Ganbarli N.F., Tkachenko N.N., Nikolaeva V.I., Tolibova G.Kh., Tral T.G., Rulev V.V., Tsipurdeeva A.A. Kisspeptin and polycystic ovary syndrome - is there any connection? Journal of Obstetrics and Women's Diseases. 2017; 66(6): 73-80 (in Russian). https://dx.doi.org/10.17816/JOWD66673-80].
  19. Emanuel R.H.K., Roberts J., Docherty P.D., Lunt H., Campbell R.E., Möller K. A review of the hormones involved in the endocrine dysfunctions of polycystic ovary syndrome and their interactions. Front. Endocrinol. (Lausanne). 2022; 13: 1017468. https://dx.doi.org/10.3389/fendo.2022.1017468
  20. Bednarz K., Kowalczyk K., Cwynar M., Czapla D., Czarkowski W. et al. The role of Glp-1 receptor agonists in insulin resistance with concomitant obesity treatment in polycystic ovary syndrome. Int. J. Mol. Sci. 2022; 23(8): 4334. https://dx.doi.org/10.3390/ijms23084334
  21. Houston E.J., Templeman N.M. Reappraising the relationship between hyperinsulinemia and insulin resistance in PCOS. J. Endocrinol. 2025; 265(2):e240269. https://dx.doi.org/10.1530/JOE-24-0269
  22. Wu C., Wei K., Jiang Z. 5α-reductase activity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Reprod. Biol. Endocrinol. 2017; 15(1):21. https://dx.doi.org/10.1186/s12958-017-0242-9
  23. Xu Y., Qiao J. Association of insulin resistance and elevated androgen levels with polycystic ovarian syndrome (PCOS): A review of literature. J. Healthc. Eng. 2022; 2022: 9240569. https://dx.doi.org/10.1155/2022/9240569
  24. Lim S.S., Davies M.J., Norman R.J., Moran L.J. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum. Reprod. Update. 2012; 18(6): 618-37. https://dx.doi.org/10.1093/humupd/dms030
  25. Wanderley M.D.S., Pereira L.C.R., Santos C.B., Cunha V.S.D., Neves M.V.J. Association between insulin resistance and cardiovascular risk factors in polycystic ovary syndrome patients. Rev. Bras. Ginecol. Obstet. 2018;40(4):188-95. https://dx.doi.org/10.1055/s-0038-1642634
  26. Kałużna M., Krauze T., Ziemnicka K., Wachowiak-Ochmańska K., Kaczmarek J., Janicki A. et al. Cardiovascular, anthropometric, metabolic and hormonal profiling of normotensive women with polycystic ovary syndrome with and without biochemical hyperandrogenism. Endocrine. 2021; 72(3): 882-92. https://dx.doi.org/10.1007/s12020-021-02648-7
  27. Теплюк Д.А., Семенистая М.Ч., Сороколетов С.М., Лазебник Л.Б., Павлов Ч.С. Факторы риска прогрессирования неалкогольной жировой болезни печени. Экспериментальная и клиническая гастроэнтерология. 2021; 192(8): 167-74. https://dx.doi.org/10.31146/1682-8658-ecg-192-8-167-174 [Teplyuk D.A., Semenistaya M.C., Sorokoletov S.M., Lazebnik L.B., Pavlov C.S. Risk factors for the progression of non-alcoholic fatty liver disease. Experimental and Clinical Gastroenterology. 2021; 192(8): 167-74 (in Russian). https://doi.org/10.31146/1682-8658-ecg-192-8-167-174].
  28. Harsha Varma S., Tirupati S., Pradeep T.V.S., Sarathi V., Kumar D. Insulin resistance and hyperandrogenemia independently predict nonalcoholic fatty liver disease in women with polycystic ovary syndrome. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2019; 13(2): 1065-9. https://dx.doi.org/10.1016/j.dsx.2018.12.020
  29. Abusailik M.A., Muhanna A.M., Almuhisen A.A., Alhasanat A.M., Alshamaseen A.M., Bani Mustafa S.M. et al. Cutaneous manifestation of polycystic ovary syndrome. Dermatology Reports. 2021; 13(2): 8799. https://dx.doi.org/10.4081/dr.2021.8799
  30. Yarmolinskaya M.I., Glavnova O.B., Vorokhobina N.V., Velikanova L.I., Malevanaya E.V. New characteristics of polycystic ovary syndrome phenotypes according to gas chromatography-mass spectrometry-based study of urinary steroid metabolome. Minerva Obstet Gynecol. 2025; 77(2): 93-102. https://dx.doi.org/10.23736/S2724-606X.24.05461-7
  31. Kicińska A.M., Maksym R.B., Zabielska-Kaczorowska M.A., Stachowska A., Babińska A. Immunological and metabolic causes of infertility in polycystic ovary syndrome. Biomedicines. 2023; 11(6):1567. https://dx.doi.org/10.3390/biomedicines11061567
  32. Zhang Q., Yang Z., Ou X., Zhang M., Qin X., Wu G. The role of immunity in insulin resistance in patients with polycystic ovary syndrome. Front Endocrinol (Lausanne). 2025; 15: 1464561. https://dx.doi.org/10.3389/fendo.2024.1464561
  33. Deng H., Chen Y., Xing J., Zhang N., Xu L. Systematic low-grade chronic inflammation and intrinsic mechanisms in polycystic ovary syndrome. Front. Immunol. 2024; 15: 1470283. https://dx.doi.org/10.3389/fimmu.2024.1470283
  34. Dumesic D.A., Phan J.D., Leung K.L., Grogan T.R., Ding X., Li X. et al. Adipose insulin resistance in normal-weight women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab. 2019; 104(6): 2171-83. https://dx.doi.org/10.1210/jc.2018-02086
  35. Yamanouchi D. The roles of incretin hormones gip and glp-1 in metabolic and cardiovascular health: a comprehensive review. Int. J. Mol. Sci. 2025; 27(1): 27. https://dx.doi.org/10.3390/ijms27010027
  36. Holst J.J. The incretin system in healthy humans: The role of GIP and GLP-1. Metabolism. 2019; 96: 46-55. https://dx.doi.org/10.1016/j.metabol.2019.04.014
  37. Uenoyama Y., Inoue N., Nakamura S., Tsukamura H. Central mechanism controlling pubertal onset in mammals: A triggering role of kisspeptin. Front Endocrinol. (Lausanne). 2019; 10: 312. https://dx.doi.org/10.3389/fendo.2019.00312
  38. Главнова О.Б., Кузнецова А.А. Беспалова О.Н. Влияние семаглутида и тирзепатида на репродуктивную систему женщин с ожирением: литературный обзор. Женское здоровье и репродукция. 2026; 2(71). https://dx.doi.org/10.31550/2712-8598-2026-2-7-ZhZiR [Glavnova O.B., Kuznetsova A.A., Bespalova O.N. The effect of semaglutide and tirzepatide on the reproductive system of women with obesity: a literature review. Women's Health and Reproduction. 2026; 2(71) (in Russian). https://dx.doi.org/10.31550/2712-8598-2026-2-7-ZhZiR]
  39. Sola-Leyva A., Pathare A.D.S., Apostolov A., Aleksejeva E., Kask K., Tammiste T. et al. The hidden impact of GLP-1 receptor agonists on endometrial receptivity and implantation. Acta Obstet. Gynecol. Scand. 2025; 104(2):258-66. https://dx.doi.org/10.1111/aogs.15010
  40. Voros C., Chatzinikolaou F., Papapanagiotou I., Polykalas S., Mavrogianni D., Koulakmanidis A.M. et al. A systematic review on GLP-1 receptor agonists in reproductive health: Integrating IVF data, ovarian physiology and molecular mechanisms. Int. J. Mol. Sci. 2026; 27(2): 759. https://dx.doi.org/10.3390/ijms27020759
  41. Singh S., Pal N., Shubham S., Sarma D.K., Verma V., Marotta F. et al. Polycystic ovary syndrome: Etiology, current management, and future therapeutics. J. Clin. Med. 2023; 12(4): 1454. https://dx.doi.org/10.3390/jcm12041454
  42. Dong J., Rees D.A. Polycystic ovary syndrome: pathophysiology and therapeutic opportunities. BMJ Med. 2023; 2(1): e000548. https://dx.doi.org/10.1136/bmjmed-2023-000548
  43. Hamsho M., Shkorfu W., Bensaoua M., Martins C.E.C., Hacibayram H., Fadel A. et al. Effects of probiotic and metformin co-administration versus metformin monotherapy on anthropometric measurements, hormones, and glucolipid profile in women with polycystic ovary syndrome: a systematic review and meta-analysis. Front. Endocrinol. (Lausanne). 2026; 17: 1802369. https://dx.doi.org/10.3389/fendo.2026.1802369
  44. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Синдром поликистозных яичников. 2025. Доступно по: https://cr.minzdrav.gov.ru/preview-cr/910_1 [Ministry of Health of the Russian Federation. Clinical guidelines. Polycystic ovary syndrome. 2025. Available at: https://cr.minzdrav.gov.ru/preview-cr/910_1 (in Russian)].
  45. Дикке Г.Б., Духанин А.С. Миоинозитол и D-хироинозитол в лечении пациенток с ановуляторным бесплодием, связанным с метаболическими нарушениями. Дискуссионные вопросы. Акушерство и гинекология. 2025; 7: 175-86. https://dx.doi.org/10.18565/aig.2025.173 [Dikke G.B., Dukhanin A.S. Myoinositol and D-chiroinositol in the treatment of patients with anovulatory infertility associated with metabolic disorders: debatable issues. Obstetrics and Gynecology. 2025; (7): 175-86 (in Russian). https://dx.doi.org/10.18565/aig.2025.173]
  46. Fitz V., Graca S., Mahalingaiah S., Liu J., Lai L., Butt A. et al. Inositol for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 Update of the International Evidence-based PCOS Guidelines. J. Clin. Endocrinol. Metab. 2024; 109(6):1630-55. https://dx.doi.org/10.1210/clinem/dgad762.
  47. Hoteit B.H., Kotaich J., Ftouni H., Hazime F., Safawi A., Masri R. et al. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. Ther. Adv. Endocrinol. Metab. 2025; 16: 20420188251383064. https://dx.doi.org/10.1177/20420188251383064
  48. Carmina E., Longo R.A. Semaglutide treatment of excessive body weight in obese PCOS patients unresponsive to lifestyle programs. J. Clin. Med. 2023; 12(18): 5921. https://dx.doi.org/10.3390/jcm12185921
  49. Elkind-Hirsch K.E., Chappell N., Shaler D., Storment J., Bellanger D. Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study. Fertil. Steril. 2022; 118(2): 371-81. https://dx.doi.org/10.1016/j.fertnstert.2022.04.027
  50. Frøssing S., Nylander M., Chabanova E., Frystyk J., Holst J.J., Kistorp C. et al. Effect of liraglutide on ectopic fat in polycystic ovary syndrome: A randomized clinical trial. Diabetes Obes. Metab. 2018; 20(1): 215-8. https://dx.doi.org/10.1111/dom.13053
  51. Ferdous J., Hossain M.M., Faika M.J., Begum M., Mahjabeen S., Jahan I.A. et al. Role of tirzepatide in obesity management among women with polycystic ovary syndrome. International Journal of Diabetes and Endocrinology. 2025; 10(2): 37-44. https://dx.doi.org/10.11648/j.ijde.20251002.12
  52. Ушанова Ф.О., Демидова Т.Ю. Синдром поликистозных яичников сквозь призму кардиометаболического риска: от патогенеза к новым терапевтическим стратегиям. FOCUS Эндокринология. 2026; 7(1): 66-75. https://dx.doi.org/10.62751/2713-0177-2026-7-1-09 [Ushanova F.O., Demidova T.Yu. Polycystic ovary syndrome through the prism of cardiometabolic risk: From pathogenesis to new therapeutic strategies. FOCUS. Endocrinology. 2026;7(1):66-75 (in Russian). https://dx.doi.org/10.62751/2713-0177-2026-7-1-09].
  53. Чащин М.Г., Величко А.М., Глечян А.М., Емельянов А.В., Горшков А.Ю., Драпкина О.М. Роль агонистов рецепторов глюкагоноподобного пептида-1 в лечении дислипидемии у пациентов с избыточной массой тела и ожирением (обзор). Рациональная Фармакотерапия в Кардиологии. 2026; 22(1): 107-15. https://dx.doi.org/10.20996/1819-6446-2026-3246 [Chashchin M.G., Velichko A.M., Glechyan A.M., Emelyanov A.V., Gorshkov A.Y., Drapkina O.M. The role of glucagon-like peptide-1 receptor agonists in the treatment of dyslipidemia in overweight and obese patients (review). Rational Pharmacotherapy in Cardiology. 2026; 22(1): 107-15 (in Russian). https://dx.doi.org/10.20996/1819-6446-2026-3246].
  54. Pugliese G., de Alteriis G., Muscogiuri G., Barrea L., Verde L., Zumbolo F. et al. Liraglutide and polycystic ovary syndrome: is it only a matter of body weight? J. Endocrinol. Invest. 2023; 46(9): 1761-74. https://dx.doi.org/10.1007/s40618-023-02084-6
  55. Zhou L., Qu H., Yang L., Shou L. Effects of GLP1RAs on pregnancy rate and menstrual cyclicity in women with polycystic ovary syndrome: a meta-analysis and systematic review. BMC Endocr. Disord. 2023; 23(1):245. https://dx.doi.org/10.1186/s12902-023-01500-5
  56. Nylander M., Frossing S., Clausen H.V., Kistorp C., Faber J., Skouby S.O. Effects of liraglutide on ovarian dysfunction in polycystic ovary syndrome: a randomized clinical trial. Reprod. Biomed. Online. 2017; 35(1): 121-7. https://dx.doi.org/10.1016/j.rbmo.2017.03.023
  57. Кожухов Н.Д., Карпова А.Р., Садретдинова А.А., Кодоева Д.Г., Карданова А.С., Прошина А.С., Авбакирова А.С., Киличев Д.Р., Метов И.Ш., Магомедов Л.М., Гацаев Д.К., Балабанова М.Э., Муталиева Х.Б., Алибекова З.М. Роль агонистов глюкагоноподобного пептида-1 в коррекции иммунных и метаболических расстройств у женщин с нарушением репродуктивной функции. Акушерство, Гинекология и Репродукция. https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2025.657 [Kozhukhov N.D., Karpova A.R., Sadretdinova A.A., Kodoeva D.G., Kardanova A.S., Proshina A.S., Avbakirova A.S., Kilichev D.R., Metov I.Sh., Magomedov L.M., Gatsaev D.K., Balabanova M.E., Mutalieva Kh.B., Alibekova Z.M. The role of glucagon-like peptide-1 receptor agonists in the correction of immune and metabolic disorders in women with reproductive dysfunction. Obstetrics, Gynecology and Reproduction (in Russsian). https://dx.doi.org/10.17749/2313-7347/ob.gyn.rep.2025.657].
  58. Bhattarai H.B., Paudel B.S., Parajuli S.R., Dahal K., Shah S., Bhattarai M. et al. Gastrointestinal side effects of the non-peptide GLP-1 receptor agonists: A systematic review and meta-analysis. Medicine (Baltimore). 2025; 104(52): e46671. https://dx.doi.org/10.1097/MD.0000000000046671
  59. Min J.S., Jo S.J., Lee S., Kim D.Y., Kim D.H., Lee C.B. et al. A Comprehensive review on the pharmacokinetics and drug-drug interactions of approved GLP-1 receptor agonists and a dual GLP-1/GIP receptor agonist. Drug Des. Devel. Ther. 2025; 19(1): 3509-37. https://dx.doi.org/10.2147/DDDT.S506957
  60. Valladares A.C., Astudillo M.A., Drinnon A.R., Dowlatshahi S., Kansara A., Shakil J. et al. Medical management of obesity: Current trends and future perspectives. Methodist Debakey Cardiovasc. J. 2025; 21(2):62-73. https://dx.doi.org/10.14797/mdcvj.1503
  61. Каронова Т.Л., Никулина А.А., Мурашева А.В., Тиселько А.В., Черникова А.Т., Шавинина А.И. и др. Место арГПП-1 и арГПП-1/ГИП в комплексной прегравидарной подготовке у женщин с ожирением. РМЖ Медицинское обозрение. 2025; 9(10): 749-56. https://dx.doi.org/10.32364/2587-6821-2025-9-10-8 [Karonova T.L., Nikulina A.A., Murasheva A.V., Tiselko A.V., Chernikova A.T., Shavinina A.I. et al. The role of GLP-1RAs and GLP-1RA/GIPRAs in comprehensive preconception care for women with obesity. RMJ Medical Review. 2025; 9(10): 749-56 (in Russian). https://dx.doi.org/10.32364/2587-6821-2025-9-10-8].
  62. Sheth K., Kim S., Porterfield L., Virani S.S., Wadhwani S., Vaughan E.M. The expanding scope of GLP-1 receptor agonists: Six uses beyond diabetes. Curr. Atheroscler. Rep. 2025; 27(1): 76. https://dx.doi.org/10.1007/s11883-025-01319-6
  63. Dehghan Z., Mohammadi-Yeganeh S., Sameni M., Mirmotalebisohi S.A., Zali H., Salehi M. Repurposing new drug candidates and identifying crucial molecules underlying PCOS pathogenesis based on bioinformatics analysis. Daru. 2021; 29(2): 353-66. https://dx.doi.org/10.1007/s40199-021-00413-9
  64. Kelly F.A., de Oliveira Macena Lôbo A., Cardoso J.H.C.O., de Moraes F.C.A. Comparison of metformin with inositol versus metformin alone in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized controlled trials. Endocrine. 2025; 87: 389-99. https://dx.doi.org/10.1007/s12020-024-04052-3
  65. Луговик И.А., Бабина А.В., Арутюнян С.С., Ермолаева Д.О., Сапарова В.Б., Кобелева Т.Н., Заикин П.Г., Микушина А.Д., Букатин А.С., Елисеев И.Е., Зайчик Б.Ц., Керученько Я.К., Охрименко И.С., Бочаров Э.В., Тальдаев А.Х., Лушпа В.А., Макаренко И.Е., Драй Р.В. Первый дженерик тирзепатида GP30931: физико-химическое и биологическое сходство с референтным лекарственным средством. Разработка и регистрация лекарственных средств. 2025; 14(2): 54-74. https://dx.doi.org/10.33380/2305-2066-2025-14-2-2084 [Lugovik I.A., Babina A.V., Arutyunyan S.S., Ermolaeva D.О., Saparova V.B., Kobeleva T.N., Zaikin P.G., Mikushina A.D., Bukatin A.S., Eliseev I.E., Zajchik B.Ts., Keruchenko Y.S., Ohrimenko I.S., Bocharov E.V., Taldaev A.Kh., Lushpa V.A., Makarenko I.E., Drai R.V. The first generic tirzepatide GP30931: physicochemical and biological similarity to the reference drug. Drug development & registration. 2025; 14(2): 54-74 (in Russian). https://dx.doi.org/10.33380/2305-2066-2025-14-2-2084].

Received 21.08.2026

Accepted 26.08.2026

About the Authors

Maria I. Yarmolinskaya, Dr. Med. Sci., Professor of the Russian Academy of Sciences, Honored Scientist of the Russian Federation, Head of the Department of Gynecology and Endocrinology, Head of the Scientific and Practical Center of Gynecologycal Endocrinology, D.O. Ott Research Institute of Obstetrics, Gynecology and Reproductology, 199034, Russia, St. Petersburg, Mendeleevskaya line, 3; Professor of the Department of Obstetrics and Gynecology, I.I. Mechnikov North‑Western State Medical University, Ministry of Health of Russia, 191015, Russia, St. Petersburg, Kirochnaya str., 41, m.yarmolinskaya@gmail.com, SPIN-code: 3686-3605, Researcher ID: P-2183-2014,
Scopus Author ID: 7801562649, https://orcid.org/0000-0002-6551-4147
Svetlana V. Yureneva, Dr. Med. Sci., Professor, Deputy Director for Science at the Institute of Oncogynecology and Mammology, Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology named after of the Ministry of Health of Russia, 117997, Russia, Moscow, Ac. Oparin str., 4,
syureneva@gmail.com, SPIN-code: 3623-9149, Researcher ID: J-5304-2017, Scopus Author ID: 56299444500, https://orcid.org/0000-0003-2864-066X
Sofya A. Cherkashina, Junior Researcher, D.O. Ott Research institute of Obstetrics, Gynecology and Reproductology, 199034, Russia, St. Petersburg, Mendeleevskaya line, 3, sonyach@list.ru, https://orcid.org/0009-0005-7208-3575
Corresponding author: Maria I. Yarmolinskaya, m.yarmolinskaya@gmail.com

Similar Articles

№7 / 2025
Shabatukova E.V., Shcherban D.A., Kudratova E.A., Skvortsova A.A., Zhukova O.V.
Modern pharmacotherapy of polycystic ovary syndrome
№7 / 2026
Bulanov D.V., Tereshchenko V.A., Abramyan S.A.
Polycystic ovary syndrome: stromal fibrosis, extracellular matrix remodeling and modern methods of morphological assessment
№6 / 2026
Dora S.V., Khalimov Yu.Sh., Bezhenar V.F., Lisker A.V., Shvets Z.V., Volkova A.R., Kolyabina A.B., Murzina O.S.
The incretin system and female reproductive function: receptor distribution, molecular mechanisms and new therapeutic prospects
№7 / 2026
Lomteva S.V., Sagamonov A.S., Kharchenko E.Yu.
The role of microRNAs that regulate oxidative stress genes in polycystic ovary syndrome
№6 / 2024
Stenyaeva N.N., Khritinin D.F., Stenyaev E.Yu.
Experience of using a combined melatonin-containing drug in the correction of sleep disorders in women
By continuing to use our site, you consent to the processing of cookies that ensure the proper functioning of the site.